Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Vascular Surgery

  Free Subscription

Articles published in Am Heart J

Retrieve available abstracts of 113 articles:
HTML format

Single Articles

    June 2022
  1. VOGEL RF, Delewi R, Wilschut JM, Lemmert ME, et al
    Pre-hospital treatment with crushed versus integral tablets of prasugrel in patients presenting with ST-Segment Elevation Myocardial Infarction - One-year follow-up results of the COMPARE CRUSH trial: One-year results from the COMPARE CRUSH trial.
    Am Heart J. 2022 Jun 4. pii: S0002-8703(22)00116.
    PubMed     Abstract available

    May 2022
  2. PARK DY, Wang P, An S, Grimshaw AA, et al
    Shortening the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Acute Coronary Syndrome: A Systematic Review and Meta-analysis: Shortening DAPT after PCI for ACS.
    Am Heart J. 2022 May 30. pii: S0002-8703(22)00113.
    PubMed     Abstract available

  3. OMEROVIC E, Erlinge D, Koul S, Frobert O, et al
    Rationale and Design of Switch Swedeheart: A Registry-Based, Stepped-Wedge, Cluster-Randomized, Open-Label Multicenter Trial to Compare Prasugrel and Ticagrelor for Treatment of Patients with Acute Coronary Syndrome.
    Am Heart J. 2022 May 26. pii: S0002-8703(22)00112.
    PubMed     Abstract available

  4. CANTOR WJ, Tan M, Berwanger O, Lavi S, et al
    Morphine and Clinical Outcomes in Patients with ST segment elevation Myocardial Infarction Treated with Fibrinolytic and Antiplatelet Therapy: Insights from the TREAT Trial.
    Am Heart J. 2022 May 6. pii: S0002-8703(22)00089.
    PubMed     Abstract available

  5. GAO W, Zhong X, Ma Y, Huang D, et al
    A Randomized Multicenter Trial to Evaluate Early Invasive Strategy for Patients with Acute ST-segment Elevation Myocardial Infarction Presenting 24-48 Hours from Symptom Onset: protocol of the RESCUE-MI study.
    Am Heart J. 2022 May 4. pii: S0002-8703(22)00087.
    PubMed     Abstract available

    April 2022
  6. DE OLIVEIRA MARREIROS DJ, Tomsic A, van Brakel TJ, Hamming JF, et al
    Computed tomography follow-up after elective proximal aortic surgery: less is more?
    Am Heart J. 2022 Apr 15. pii: S0002-8703(22)00068.
    PubMed     Abstract available

  7. GARG A, Rout A, Farhan S, Waxman S, et al
    Dual Antiplatelet Therapy Duration after Percutaneous Coronary Intervention using Drug Eluting Stents in High Bleeding Risk Patients: A Systematic Review and Meta-analysis.
    Am Heart J. 2022 Apr 15. pii: S0002-8703(22)00076.
    PubMed     Abstract available

  8. BAGIELLA E, Puskas JD, Moskowitz AJ, Gelijns AC, et al
    Rationale and design of a randomized trial evaluating an external support device for saphenous vein coronary grafts.
    Am Heart J. 2022;246:12-20.
    PubMed     Abstract available

    March 2022
  9. DUCROCQ G, Bhatt DL, Lee JJ, Kui N, et al
    Balance of Benefit and Risk of Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease According to Bleeding Risk Assessment With the CRUSADE Score: Data From THEMIS and THEMIS PCI: Abbreviated title: Bleeding risk stratification of ti
    Am Heart J. 2022 Mar 20. pii: S0002-8703(22)00055.
    PubMed     Abstract available

  10. GENEREUX P, Chernin G, Assali AR, Peruga JZ, et al
    Double-Blind, Placebo-Controlled Evaluation of Biorest Liposomal Alendronate in Diabetic Patients Undergoing PCI: The BLADE-PCI Trial: The BLADE-PCI Trial.
    Am Heart J. 2022 Mar 16. pii: S0002-8703(22)00052.
    PubMed     Abstract available

  11. GENEREUX P, Kirtane AJ, Kandzari DE, Armstrong EJ, et al
    Randomized Evaluation of Vessel Preparation With Orbital Atherectomy Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Artery Lesions: Design and Rationale of the ECLIPSE Trial.
    Am Heart J. 2022 Mar 11. pii: S0002-8703(22)00051.
    PubMed     Abstract available

    February 2022
  12. O'NEILL WW, Anderson M, Burkhoff D, Grines CL, et al
    Improved Outcomes in Patients with Severely Depressed LVEF Undergoing Percutaneous Coronary Intervention with Contemporary Practices: Impella-Supported High-Risk Percutaneous Coronary Intervention in Patients with Severely Depressed LVEF.
    Am Heart J. 2022 Feb 19. pii: S0002-8703(22)00039.
    PubMed     Abstract available

    January 2022
  13. KLINGENBERG R, Stahli BE, Heg D, Denegri A, et al
    Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial.
    Am Heart J. 2022 Jan 26. pii: S0002-8703(22)00010.
    PubMed     Abstract available

  14. OTOWA K, Kohsaka S, Sawano M, Matsuura S, et al
    One-year Outcome after Percutaneous Coronary Intervention in Nonagenarians: Insights from the J-PCI OUTCOME Registry.
    Am Heart J. 2022 Jan 8. pii: S0002-8703(22)00004.
    PubMed     Abstract available

  15. HARIRI E, Kassas I, Hammoud MA, Hansra B, et al
    Same Day Discharge Following Non-elective PCI for Non-ST Elevation Acute Coronary Syndromes.
    Am Heart J. 2022 Jan 6. pii: S0002-8703(21)00497.
    PubMed     Abstract available

  16. HARA H, Serruys PW, O'Leary N, Gao C, et al
    Angiography-derived physiology guidance versus usual care in an All-comers PCI population treated with the Healing-Targeted Supreme stent and Ticagrelor monotherapy: PIONEER IV trial design.
    Am Heart J. 2022 Jan 3. pii: S0002-8703(21)00500.
    PubMed     Abstract available

  17. AMIN AP, Frogge N, Kulkarni H, Ridolfi G, et al
    The bleeding risk treatment paradox at the physician and hospital level: Implications for reducing bleeding in patients undergoing percutaneous coronary intervention.
    Am Heart J. 2022;243:221-231.
    PubMed     Abstract available

    December 2021
  18. SIDHU MS, Lyubarova R, Bangalore S, Bonaca MP, et al
    Challenges of Long-term Dual Antiplatelet Therapy Use Following Acute Coronary Syndromes: Patient Selection for Long-term DAPT After ACS.
    Am Heart J. 2021 Dec 18. pii: S0002-8703(21)00478.
    PubMed     Abstract available

  19. PASALA S, Cooper LB, Psotka MA, Sinha SS, et al
    The Influence of Heart Failure on Clinical and Economic Outcomes among Older Adult >/=75 Years of Age with Acute Myocardial Infarction.
    Am Heart J. 2021 Dec 16. pii: S0002-8703(21)00474.
    PubMed     Abstract available

  20. CHRISTENSEN DM, Schjerning AM, Sindet-Pedersen C, Lamberts M, et al
    Outcomes of prolonged dual anti-platelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a nationwide registry-based study.
    Am Heart J. 2021 Dec 10. pii: S0002-8703(21)00471.
    PubMed     Abstract available

  21. MONTOY JCC, Shen YC, Krumholz HM, Hsia RY, et al
    Association of STEMI regionalization of care with de facto NSTEMI regionalization.
    Am Heart J. 2021;242:1-5.
    PubMed     Abstract available

    November 2021
  22. HUANG D, Wu H, Zhou J, Zhong X, et al
    Intravenous Nicorandil During Primary Percutaneous Coronary intervention in Patients with ST-Elevation Myocardial Infarction: Rationale and Design of the CLinical Efficacy and sAfety of intravenous Nicorandil (CLEAN) trial.
    Am Heart J. 2021 Nov 13. pii: S0002-8703(21)00448.
    PubMed     Abstract available

  23. KOSHY AN, Dinh DT, Fulcher J, Brennan AL, et al
    Long-Term Mortality in Asymptomatic Patients with Stable Ischemic Heart Disease undergoing Percutaneous Coronary Intervention.
    Am Heart J. 2021 Nov 12. pii: S0002-8703(21)00449.
    PubMed     Abstract available

  24. VALLABHAJOSYULA S, Bhopalwala HM, Sundaragiri PR, Dewaswala N, et al
    Cardiogenic Shock Complicating Non-ST-Segment Elevation Myocardial Infarction: An 18-Year Study.
    Am Heart J. 2021 Nov 11. pii: S0002-8703(21)00445.
    PubMed     Abstract available

  25. BOHM F, Mogensen B, Ostlund O, Engstrom T, et al
    The Full Revasc (Ffr-gUidance for compLete non-cuLprit REVASCularization) Registry-based randomized clinical trial.
    Am Heart J. 2021;241:92-100.
    PubMed     Abstract available

    October 2021
  26. AMINIAN A, Sgueglia GA, Wiemer M, Gasparini GL, et al
    Distal versus conventional radial access for coronary angiography and intervention: design and rationale of DISCO RADIAL Study.
    Am Heart J. 2021 Oct 16. pii: S0002-8703(21)00432.
    PubMed     Abstract available

    September 2021
  27. TAVENIER AH, Hermanides RS, Ottervanger JP, Belitser SV, et al
    Impact of vomiting on P2Y12 platelet inhibition in patients with ST-elevation myocardial infarction: a pre-specified sub-analysis of the ON-TIME 3 trial.
    Am Heart J. 2021 Sep 18. pii: S0002-8703(21)00209.
    PubMed     Abstract available

  28. DE KONING MLY, van Dorp P, Assa S, Hartman MHT, et al
    Rationale and Design of the Groningen Intervention Study for the Preservation of Cardiac Function with Sodium Thiosulfate after ST-segment Elevation Myocardial Infarction (GIPS-IV) Trial.
    Am Heart J. 2021 Sep 14. pii: S0002-8703(21)00210.
    PubMed     Abstract available

  29. NARCISSE DI, Ford CB, Weissler EH, Lippmann SJ, et al
    The association of healthcare disparities and patient-specific factors on clinical outcomes in peripheral artery disease.
    Am Heart J. 2021;239:135-146.
    PubMed     Abstract available

    July 2021
  30. HSU B, Carcel C, Wang X, Peters SAE, et al
    Sex differences in emergency medical services management of patients with myocardial infarction: analysis of routinely collected data for over 110,000 patients.
    Am Heart J. 2021 Jul 24. pii: S0002-8703(21)00188.
    PubMed     Abstract available

    June 2021
  31. YONG CM, Spinelli KJ, Chiu ST, Jones B, et al
    Cardiovascular Procedural Deferral and Outcomes over COVID-19 Pandemic Phases: A Multi-Center Study.
    Am Heart J. 2021 Jun 25. pii: S0002-8703(21)00167.
    PubMed     Abstract available

  32. HU X, Wang Y
    Importance of complete revascularization and surgical techniques when comparing outcomes of CABG with PCI.
    Am Heart J. 2021;236:107-108.

    May 2021
  33. BAJAJ R, Parasa R, Ramasamy A, Makariou N, et al
    Computerized technologies informing cardiac catheterization and guiding coronary intervention.
    Am Heart J. 2021 May 30. pii: S0002-8703(21)00146.
    PubMed     Abstract available

  34. YERASI C, Case BC, Chezar-Azerrad C, Forrestal BJ, et al
    Cangrelor vs. Glycoprotein IIb/IIIa Inhibitors During Percutaneous Coronary Intervention.
    Am Heart J. 2021 May 4. pii: S0002-8703(21)00115.
    PubMed     Abstract available

  35. MADSEN JMM, Jacobsen MRR, Sabbah M, Topal DGG, et al
    Long-Term Prognostic Outcomes and Implication of Oral Anticoagulants in Patients with New-Onset Atrial Fibrillation following ST-Segment Elevation Myocardial Infarction.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00114.
    PubMed     Abstract available

  36. SIDEBOTTOM AC, Miedema MD, Benson G, Vacquier M, et al
    The Impact of a Population-based Prevention Program on Cardiovascular Events: Findings from the Heart of New Ulm Project.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00112.
    PubMed     Abstract available

    April 2021
  37. SINGH H, Mehta RH, O'Neill W, Kapur NK, et al
    Clinical Features and Outcomes in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction: Early versus Recent Experience with Impella.
    Am Heart J. 2021 Apr 10. pii: S0002-8703(21)00090.
    PubMed     Abstract available

    March 2021
  38. QU J, Du J, Rao C, Chen S, et al
    Effect of a Smartphone-Based Intervention on Secondary Prevention Medication Prescriptions After Coronary Artery Bypass Graft Surgery: The MISSION-1 Randomized Controlled Trial.
    Am Heart J. 2021 Mar 6. pii: S0002-8703(21)00070.
    PubMed     Abstract available

  39. FABRIS E, Ten Berg JM, Hermanides RS, Ottervanger JP, et al
    NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial.
    Am Heart J. 2021;233:78-85.
    PubMed     Abstract available

    February 2021
  40. BATCHELOR WB, Damluji AA, Yong C, Fiuzat M, et al
    Am Heart J. 2021 Feb 23. pii: S0002-8703(21)00035.
    PubMed     Abstract available

  41. GE Z, Gao XF, Kan J, Kong XQ, et al
    Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicent
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00053.
    PubMed     Abstract available

  42. PILGRIM T, Rothenbuhler M, Siontis GC, Kandzari DE, et al
    Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients undergoing percutaneous coronary intervention: a meta-analysis of individual patient data from five randomized trials.
    Am Heart J. 2021 Feb 17. pii: S0002-8703(21)00048.
    PubMed     Abstract available

  43. PRABHU KM, Don C, Sayre GG, Kearney KE, et al
    Interventional Cardiologists' Perceptions of Percutaneous Coronary Intervention Quality Measurement and Feedback.
    Am Heart J. 2021 Feb 7. pii: S0002-8703(21)00032.
    PubMed     Abstract available

  44. BROPHY TJ, Warsavage TJ, Hebbe AL, Plomondon ME, et al
    Percutaneous Coronary Intervention in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction: Insights from the VA CART Program.
    Am Heart J. 2021 Feb 7. pii: S0002-8703(21)00034.
    PubMed     Abstract available

  45. PEREIRA NL, Avram R, So DY, Iturriaga E, et al
    Rationale and design of the TAILOR-PCI digital study: Transitioning a randomized controlled trial to a digital registry.
    Am Heart J. 2021;232:84-93.
    PubMed     Abstract available

  46. BRAIK N, Guedeney P, Behnes M, Desch S, et al
    Impact of chronic total occlusion and revascularization strategy in patients with infarct-related cardiogenic shock: A subanalysis of the culprit-shock trial.
    Am Heart J. 2021;232:185-193.
    PubMed     Abstract available

  47. LOTTES AE, Whatley EM, Royce SM, Bertges DJ, et al
    Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program.
    Am Heart J. 2021;232:71-83.
    PubMed     Abstract available

    January 2021
  48. SAWANO M, Spertus JA, Masoudi FA, Rumsfeld JS, et al
    Bleeding Avoidance Strategies and Percutaneous Coronary Intervention Outcomes: A Ten-year Observation from a Japanese Multicenter Registry: Post-PCI Bleeding Avoidance and Outcomes.
    Am Heart J. 2021 Jan 17. pii: S0002-8703(21)00014.
    PubMed     Abstract available

  49. GE Z, Kan J, Gao XF, Kong XQ, et al
    Comparison of intravascular ultrasound-guided with angiography-guided double kissing crush stenting for patients with complex coronary bifurcation lesions: rationale and design of a prospective, randomized and multicenter DKCRUSH VIII trial.
    Am Heart J. 2021 Jan 16. pii: S0002-8703(21)00015.
    PubMed     Abstract available

  50. ZHAO Y, Sivaswamy A, Lee MK, Izadnegahdar M, et al
    A Feasibility Study for CODE-MI: High-Sensitivity Cardiac Troponin - Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women.
    Am Heart J. 2021 Jan 15. pii: S0002-8703(21)00012.
    PubMed     Abstract available

  51. YANKEY GS, Jackson LR, Marts C, Chiswell K, et al
    African American-Caucasian American Differences in Aortic Valve Replacement in Patients with Severe Aortic Stenosis: Racial Differences in AVR.
    Am Heart J. 2021 Jan 13. pii: S0002-8703(21)00009.
    PubMed     Abstract available

  52. THIELE H, Freund A, Gimenez MR, de Waha-Thiele S, et al
    Extracorporeal life support in patients with acute myocardial infarction complicated by cardiogenic shock - Design and rationale of the ECLS-SHOCK trial.
    Am Heart J. 2021 Jan 8. pii: S0002-8703(21)00004.
    PubMed     Abstract available

  53. MARBACH JA, Wells G, Santo PD, So D, et al
    Acute Kidney Injury after Radial or Femoral Artery Access in ST-Segment Elevation Myocardial Infarction: AKI-SAFARI.
    Am Heart J. 2021 Jan 7. pii: S0002-8703(21)00001.
    PubMed     Abstract available

  54. FAGEL ND, Amoroso G, Vink MA, Slagboom T, et al
    An immediate or early invasive strategy in non-ST-elevation acute coronary syndrome: the OPTIMA-2 randomized controlled trial.
    Am Heart J. 2021 Jan 7. pii: S0002-8703(21)00003.
    PubMed     Abstract available

  55. VALGIMIGLI M, Cao D, Makkar RR, Bangalore S, et al
    Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent.
    Am Heart J. 2021;231:147-156.
    PubMed     Abstract available

    December 2020
  56. MALIK AO, Amin A, Kennedy K, Qintar M, et al
    Patient-centered contrast thresholds to reduce acute kidney injury in high-risk patients undergoing percutaneous coronary intervention.
    Am Heart J. 2020 Dec 23. pii: S0002-8703(20)30415.
    PubMed     Abstract available

  57. CHOUDHARY R, Kumari V
    Aspirin versus P2Y12 inhibitor-based monotherapy after percutaneous coronary intervention.
    Am Heart J. 2020;230:99.

  58. KUNO T, Ueyama H, Takagi H, Bangalore S, et al
    Choosing between aspirin or P2Y12 monotherapy after short course of DAPT.
    Am Heart J. 2020;230:100.

  59. JOYCE J, O'Leary ET, Mah DY, Harrild DM, et al
    Cardiac resynchronization therapy improves the ventricular function of patients with Fontan physiology.
    Am Heart J. 2020;230:82-92.
    PubMed     Abstract available

  60. DE LA PAZ A, Orgel R, Hartsell SE, Pauley E, et al
    Getting cardiogenic shock patients to the right place-How initial intensive care unit triage decisions impact processes of care and outcomes.
    Am Heart J. 2020;230:66-70.
    PubMed     Abstract available

    November 2020
  61. DAYAN V, Myers P
    Comparing apples and oranges and adding inches to meters: Is this the way to conduct rigorous meta-analyses of PCI versus CABG in left main coronary disease?
    Am Heart J. 2020;229:180-181.

  62. KUNO T, Ueyama H, Rao SV, Cohen MG, et al
    Meta-analysis of PCI vs. CABG for left main disease revisited.
    Am Heart J. 2020;229:178-179.

  63. YANNOPOULOS D, Kalra R, Kosmopoulos M, Walser E, et al
    Rationale and methods of the Advanced R(2)Eperfusion STrategies for Refractory Cardiac Arrest (ARREST) trial.
    Am Heart J. 2020;229:29-39.
    PubMed     Abstract available

    October 2020
  64. JAWITZ OK, Stebbins AS, Raman V, Alhanti B, et al
    Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial.
    Am Heart J. 2020 Oct 27. pii: S0002-8703(20)30352.
    PubMed     Abstract available

  65. JAWITZ OK, Cox ML, Ranney D, Williams JB, et al
    Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial.
    Am Heart J. 2020;228:91-97.
    PubMed     Abstract available

  66. LI Y, Wang X, Bao D, Liao Z, et al
    Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial.
    Am Heart J. 2020;228:8-16.
    PubMed     Abstract available

    September 2020
  67. BIAGIONI RB, Lopes RD, Agati LB, Sacilotto R, et al
    Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial.
    Am Heart J. 2020;227:100-106.
    PubMed     Abstract available

    August 2020
  68. LAURIDSEN MD, Rorth R, Lindholm MG, Kjaergaard J, et al
    Trends in first-time hospitalization, management, and short-term mortality in acute myocardial infarction-related cardiogenic shock from 2005-2017: A nationwide cohort study.
    Am Heart J. 2020 Aug 27. pii: S0002-8703(20)30242.
    PubMed     Abstract available

  69. GUTIERREZ JA, Heizer GM, Jones WS, Rockhold FW, et al
    CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial.
    Am Heart J. 2020;229:118-120.

  70. KANG DY, Ahn JM, Park H, Lee PH, et al
    Comparison of optical coherence tomography-guided versus intravascular ultrasound-guided percutaneous coronary intervention: Rationale and design of a randomized, controlled OCTIVUS trial.
    Am Heart J. 2020;228:72-80.
    PubMed     Abstract available

  71. SHLOFMITZ E, Torguson R, Mintz GS, Zhang C, et al
    The IMPact on Revascularization Outcomes of intraVascular ultrasound-guided treatment of complex lesions and Economic impact (IMPROVE) trial: Study design and rationale.
    Am Heart J. 2020;228:65-71.
    PubMed     Abstract available

  72. KATZ JN
    Back to the future-Are we ready for a randomized trial of surgical versus percutaneous revascularization in cardiogenic shock?
    Am Heart J. 2020;226:264-266.

    July 2020
  73. STAHLI BE, Varbella F, Schwarz B, Nordbeck P, et al
    Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease.
    Am Heart J. 2020;228:98-108.
    PubMed     Abstract available

  74. PLOUMEN EH, Buiten RA, Doggen CJM, Stoel MG, et al
    New-generation drug-eluting coronary stents in octogenarians: Patient-level pooled analysis from the TWENTE I-IV trials.
    Am Heart J. 2020;228:109-115.
    PubMed     Abstract available

  75. LI Y, Jing Q, Wang B, Wang X, et al
    Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of t
    Am Heart J. 2020;228:1-7.
    PubMed     Abstract available

  76. YU C, Liu C, Du J, Liu H, et al
    Smartphone-based application to improve medication adherence in patients after surgical coronary revascularization.
    Am Heart J. 2020;228:17-26.
    PubMed     Abstract available

  77. SILVAIN J, Cayla G, Beygui F, Range G, et al
    Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study.
    Am Heart J. 2020;225:27-37.
    PubMed     Abstract available

    June 2020
  78. YAN Y, Wang X, Guo J, Li Y, et al
    Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial i
    Am Heart J. 2020;227:19-30.
    PubMed     Abstract available

  79. DEN DEKKER WK, Van Mieghem NM, Bennett J, Sabate M, et al
    Percutaneous complete revascularization strategies using sirolimus-eluting biodegradable polymer-coated stents in patients presenting with acute coronary syndrome and multivessel disease: Rationale and design of the BIOVASC trial.
    Am Heart J. 2020;227:111-117.
    PubMed     Abstract available

  80. KUNO T, Ueyama H, Takagi H, Bangalore S, et al
    P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials.
    Am Heart J. 2020;227:82-90.
    PubMed     Abstract available

  81. KUNO T, Ueyama H, Rao SV, Cohen MG, et al
    Percutaneous coronary intervention or coronary artery bypass graft surgery for left main coronary artery disease: A meta-analysis of randomized trials.
    Am Heart J. 2020;227:9-10.
    PubMed     Abstract available

  82. LAMBERT LM, McCrindle BW, Pemberton VL, Hollenbeck-Pringle D, et al
    Longitudinal study of anthropometry in Fontan survivors: Pediatric Heart Network Fontan study.
    Am Heart J. 2020;224:192-200.
    PubMed     Abstract available

  83. ERHUN F, Kaplan RS, Narayanan VG, Brayton K, et al
    Are cost advantages from a modern Indian hospital transferable to the United States?
    Am Heart J. 2020;224:148-155.
    PubMed     Abstract available

    May 2020
  84. ARMSTRONG PW, Bogaerts K, Welsh R, Sinnaeve PR, et al
    The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients.
    Am Heart J. 2020;226:140-146.
    PubMed     Abstract available

  85. SMILOWITZ NR, Galloway AC, Ohman EM, Rao SV, et al
    Coronary revascularization and circulatory support strategies in patients with myocardial infarction, multi-vessel coronary artery disease, and cardiogenic shock: Insights from an international survey.
    Am Heart J. 2020;225:55-59.
    PubMed     Abstract available

  86. MARQUIS-GRAVEL G, Huang Z, Zelenkofske SL, Lincoff AM, et al
    Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial.
    Am Heart J. 2020;223:84-86.

  87. COSTA F, van Klaveren D, Colombo A, Feres F, et al
    A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making.
    Am Heart J. 2020;223:44-47.
    PubMed     Abstract available

    April 2020
  88. GUEDENEY P, Thiele H, Kerneis M, Barthelemy O, et al
    Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial.
    Am Heart J. 2020;225:60-68.
    PubMed     Abstract available

  89. LAINE M, Lemesle G, Burtey S, Cayla G, et al
    TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial.
    Am Heart J. 2020;225:19-26.
    PubMed     Abstract available

  90. DAN K, Shlofmitz E, Khalid N, Hideo-Kajita A, et al
    Paclitaxel-related balloons and stents for the treatment of peripheral artery disease: Insights from the Food and Drug Administration 2019 Circulatory System Devices Panel Meeting on late mortality.
    Am Heart J. 2020;222:112-120.
    PubMed     Abstract available

    March 2020
  91. YOON YH, Ahn JM, Kang DY, Park H, et al
    Pragmatic trial comparing routine versus no routine functional testing in high-risk patients who underwent percutaneous coronary intervention: Rationale and design of POST-PCI trial.
    Am Heart J. 2020;224:156-165.
    PubMed     Abstract available

  92. OSMAN M, Saleem M, Osman K, Kheiri B, et al
    Radial versus femoral access for percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: Trial sequential analysis.
    Am Heart J. 2020;224:98-104.
    PubMed     Abstract available

  93. SMILOWITZ NR, Alviar CL, Katz SD, Hochman JS, et al
    Coronary artery bypass grafting versus percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shock.
    Am Heart J. 2020 Mar 12. pii: S0002-8703(20)30080.
    PubMed     Abstract available

  94. VLACHOJANNIS GJ, Vogel RF, Wilschut JM, Lemmert ME, et al
    COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.
    Am Heart J. 2020;224:10-16.
    PubMed     Abstract available

    Consequences of impressive myectomy results in a Center of Excellence: The paradox of evidence-based medicine era.
    Am Heart J. 2020;221:157-158.

  96. G TOTH G, Lansky A, Baumbach A, Kelbaek H, et al
    Validation of the all-comers design: Results of the TARGET-AC substudy.
    Am Heart J. 2020;221:148-154.
    PubMed     Abstract available

    February 2020
  97. DAUBERT MA, White JA, Al-Khalidi HR, Velazquez EJ, et al
    Cardiac remodeling after large ST-elevation myocardial infarction in the current therapeutic era.
    Am Heart J. 2020;223:87-97.
    PubMed     Abstract available

  98. SONG L, Tu S, Sun Z, Wang Y, et al
    Quantitative flow ratio-guided strategy versus angiography-guided strategy for percutaneous coronary intervention: Rationale and design of the FAVOR III China trial.
    Am Heart J. 2020;223:72-80.
    PubMed     Abstract available

  99. JAWITZ OK, Gulack BC, Brennan JM, Thibault DP, et al
    Association of postoperative complications and outcomes following coronary artery bypass grafting.
    Am Heart J. 2020;222:220-228.
    PubMed     Abstract available

  100. D'ASCENZO F, Biole C, Raposeiras-Roubin S, Gaido F, et al
    Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.
    Am Heart J. 2020;220:108-115.
    PubMed     Abstract available

    January 2020
  101. ROMAGUERA R, Salinas P, Brugaletta S, Gomez-Lara J, et al
    Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design.
    Am Heart J. 2020;222:174-182.

  102. JEONG YJ, Park K, Kim YD
    Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography.
    Am Heart J. 2020;222:121-130.
    PubMed     Abstract available

  103. KINNAIRD T, Gallagher S, Spratt JC, Ludman P, et al
    Complex high-risk and indicated percutaneous coronary intervention for stable angina: Does operator volume influence patient outcome?
    Am Heart J. 2020;222:15-25.
    PubMed     Abstract available

  104. NANNA MG, Peterson ED, Wu A, Harding T, et al
    Age, knowledge, preferences, and risk tolerance for invasive cardiac care.
    Am Heart J. 2020;219:99-108.
    PubMed     Abstract available

    December 2019
  105. PUYMIRAT E, Simon T, de Bruyne B, Montalescot G, et al
    Rationale and design of the Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction (FLOWER-MI) trial.
    Am Heart J. 2019;222:1-7.
    PubMed     Abstract available

  106. MCCOY IE, Montez-Rath ME, Chertow GM, Chang TI, et al
    Central venous pressure and the risk of diuretic-associated acute kidney injury in patients after cardiac surgery.
    Am Heart J. 2019;221:67-73.
    PubMed     Abstract available

  107. SHLOFMITZ E, Torguson R, Zhang C, Craig PE, et al
    Impact of Intravascular Ultrasound on Outcomes Following PErcutaneous Coronary InterventioN in Complex Lesions (iOPEN Complex).
    Am Heart J. 2019;221:74-83.
    PubMed     Abstract available

  108. WILLEMSEN LM, Janssen PWA, Hackeng CM, Kelder JC, et al
    A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery-Rationale and design of the POPular CABG trial.
    Am Heart J. 2019;220:237-245.
    PubMed     Abstract available

  109. PATEL DM, Thiessen-Philbrook H, Brown JR, McArthur E, et al
    Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery.
    Am Heart J. 2019;220:253-263.
    PubMed     Abstract available

    November 2019
  110. SUTTER JS, Lokhnygina Y, Daubert JP, Bahnson T, et al
    Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation.
    Am Heart J. 2019;220:89-96.
    PubMed     Abstract available

  111. SHAVADIA JS, Granger CB, Alemayehu W, Westerhout CM, et al
    High-throughput targeted proteomics discovery approach and spontaneous reperfusion in ST-segment elevation myocardial infarction.
    Am Heart J. 2019;220:137-144.
    PubMed     Abstract available

    May 2019
  112. GELMAN A, Carlin JB, Nallamothu BK
    Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) and coronary stents: A case study in the analysis and reporting of clinical trials.
    Am Heart J. 2019;214:54-59.

    April 2019
  113. ZIMMERMANN FM, De Bruyne B, Pijls NHJ, Desai M, et al
    A protocol update of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial: A comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with
    Am Heart J. 2019;214:156-157.

Thank you for your interest in scientific medicine.

AMEDEO Vascular Surgery is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.